Naperville, IL -- (SBWIRE) -- 04/23/2015 -- Reportstack, provider of premium market research reports announces the addition of OpportunityAnalyzer: Duchenne Muscular Dystrophy-Opportunity and Market Analysis to 2019 market report to its offering

Duchenne muscular dystrophy (DMD) is a rare genetic disorder affecting approximately 1 in 3,500 newborn boys and is characterized by progressive muscle degeneration, loss of ambulation, and death by the late 20s. There are no marketed pharmacological therapies that are indicated for DMD. The current standard of care treatment involves generic corticosteroids which are used to marginally prolong muscle function but do not offer preventative treatment. The anticipated launch of PTC Therapeutics’ Translarna in 2015 in the US and 5EU, followed by the 6MM launch of Exon-skipping therapies- BioMarin/Prosensa’s drisapersen and Sarepta Therapeutics’ eteplirsen, in 2015 and 2016, respectively, are set to change the treatment landscape and drive growth in the DMD market. The publisher estimates that the uptake of Translarna and exon-skipping therapies will be very high due to the lack of effective disease-modifying therapies for DMD. The publisher estimates that the DMD market was valued at $8.2m across the 6MM in 2014, and it is expected to sharply increase to approximately $990.0m in 2019, at a Compound Annual Growth Rate (CAGR) of 160.5%.

Scope

Overview of DMD, including epidemiology, etiology, pathophysiology, symptoms and current treatment options

Annualized DMD therapeutics market revenue, annual cost of therapies and forecasts for five years to 2019.

Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the DMD therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including nonsense mutation readthrough inducer, exon-skipping therapies, synthetic electron transporter, PDE5 inhibitor.

Analysis of the current and future market competition in the US and five major EU DMD therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

List of Companies

Acceleron

Akashi

Asklepios

BioMarin

BMS

Catabasis

Eli Lilly

Italfarmaco

Milo Biotechnology

Nobelpharma

Pfizer

Prosensa

PTC

Santhera

Sarepta

Shenzhen Beike

Summit

Taiho

Tarix

Complete report is available
http://www.reportstack.com/product/199178/opportunityanalyzer-duchenne-muscular-dystrophy-opportunity-and-market-analysis-to-2019.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604